• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2022/23 年度流感季末英国初级保健中的流感疫苗有效性。

End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain.

机构信息

Statistics, Modelling and Economics Department, UK Health Security Agency, London, UK.

Clinical and Protecting Health, Public Health Scotland, Glasgow, UK.

出版信息

Influenza Other Respir Viruses. 2024 May;18(5):e13295. doi: 10.1111/irv.13295.

DOI:10.1111/irv.13295
PMID:38744684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11093773/
Abstract

BACKGROUND

The 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak late December 2022, while influenza B circulated at low levels during the latter part of the season. From September to March 2022/23, influenza vaccines were offered, free of charge, to all aged 2-13 (and 14-15 in Scotland and Wales), adults up to 49 years of age with clinical risk conditions and adults aged 50 and above across the mainland United Kingdom.

METHODS

End-of-season adjusted vaccine effectiveness (VE) estimates against sentinel primary-care attendance for influenza-like illness, where influenza infection was laboratory confirmed, were calculated using the test negative design, adjusting for potential confounders.

METHODS

Results In the mainland United Kingdom, end-of-season VE against all laboratory-confirmed influenza for all those > 65 years of age, most of whom received adjuvanted quadrivalent vaccines, was 30% (95% CI: -6% to 54%). VE for those aged 18-64, who largely received cell-based vaccines, was 47% (95% CI: 37%-56%). Overall VE for 2-17 year olds, predominantly receiving live attenuated vaccines, was 66% (95% CI: 53%-76%).

CONCLUSION

The paper provides evidence of moderate influenza VE in 2022/23.

摘要

背景

在英国,2022/23 流感季出现了流感活动反弹,此前两个流感季的活动水平较低。早期以 A(H3N2)为主,同时 A(H1N1)也有共同流行,达到 2022 年 12 月下旬的高峰,而乙型流感在本季后期的流行水平较低。从 2022 年 9 月到 2023 年 3 月,英国大陆向所有 2-13 岁(苏格兰和威尔士为 14-15 岁)、有临床风险状况的 49 岁以下成年人以及所有年龄在 50 岁及以上的成年人免费提供 2-13 岁(苏格兰和威尔士为 14-15 岁)、有临床风险状况的 49 岁以下成年人以及所有年龄在 50 岁及以上的成年人免费提供 2-13 岁(苏格兰和威尔士为 14-15 岁)、有临床风险状况的 49 岁以下成年人以及所有年龄在 50 岁及以上的成年人免费提供 2-13 岁(苏格兰和威尔士为 14-15 岁)、有临床风险状况的 49 岁以下成年人以及所有年龄在 50 岁及以上的成年人免费提供 2-13 岁(苏格兰和威尔士为 14-15 岁)、有临床风险状况的 49 岁以下成年人以及所有年龄在 50 岁及以上的成年人免费提供 2-13 岁(苏格兰和威尔士为 14-15 岁)、有临床风险状况的 49 岁以下成年人以及所有年龄在 50 岁及以上的成年人免费提供

方法

使用阴性检测设计计算针对哨点初级保健就诊的流感样疾病的季节性调整后疫苗有效性 (VE) 估计值,针对流感感染进行实验室确认,并调整潜在混杂因素。

结果

在英国大陆,≥65 岁人群的最终季节 VE 针对所有实验室确诊的流感为 30%(95%CI:-6%至 54%)。年龄在 18-64 岁的人群中,主要接种的是含佐剂的四价疫苗,VE 为 47%(95%CI:37%-56%)。2-17 岁人群的总体 VE 主要为活减毒疫苗,为 66%(95%CI:53%-76%)。

结论

该研究提供了 2022/23 年流感中度 VE 的证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1c/11093773/ddd02214f3c1/IRV-18-e13295-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1c/11093773/7cefdde46f4f/IRV-18-e13295-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1c/11093773/76e9b213fd86/IRV-18-e13295-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1c/11093773/ddd02214f3c1/IRV-18-e13295-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1c/11093773/7cefdde46f4f/IRV-18-e13295-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1c/11093773/76e9b213fd86/IRV-18-e13295-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1c/11093773/ddd02214f3c1/IRV-18-e13295-g003.jpg

相似文献

1
End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain.2022/23 年度流感季末英国初级保健中的流感疫苗有效性。
Influenza Other Respir Viruses. 2024 May;18(5):e13295. doi: 10.1111/irv.13295.
2
End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19.2018/19 年度英国初级保健中老年和儿童季节性流感疫苗的效果。
Vaccine. 2020 Jan 16;38(3):489-497. doi: 10.1016/j.vaccine.2019.10.071. Epub 2019 Nov 1.
3
Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.2014/15 年在欧洲,I-MOVE 多中心病例对照研究中,在甲型 H1N1pdm09、乙型和漂移型甲型 H3N2 流感共同流行的季节,初级保健患者中预防实验室确诊流感的疫苗效力。
Euro Surveill. 2016;21(7):pii=30139. doi: 10.2807/1560-7917.ES.2016.21.7.30139.
4
Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results.三价季节性流感疫苗在英国初级保健中预防实验室确诊流感的效果:2012/13 季末结果。
Euro Surveill. 2014 Jul 10;19(27):5-13.
5
Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results.英国初级保健中季节性流感疫苗预防实验室确诊流感的效果:2014/15 季末结果。
Euro Surveill. 2015;20(36). doi: 10.2807/1560-7917.ES.2015.20.36.30013.
6
End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18.2017/18 年度英国成人和儿童季节性流感疫苗的有效性。
Euro Surveill. 2019 Aug;24(31). doi: 10.2807/1560-7917.ES.2019.24.31.1800488.
7
Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results.英国初级保健中成人和儿童季节性流感疫苗预防实验室确诊流感的有效性:2015/16 赛季末结果
Euro Surveill. 2016 Sep 22;21(38). doi: 10.2807/1560-7917.ES.2016.21.38.30348.
8
Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13.在一个同时流行三种流感病毒型/亚型的季节里,对欧洲流感疫苗有效性的评估:I-MOVE 多中心病例对照研究,2012/13 年流感季节。
Euro Surveill. 2014 Feb 13;19(6):20701. doi: 10.2807/1560-7917.es2014.19.6.20701.
9
Uptake and effectiveness of influenza vaccine in those aged 65 years and older in the United Kingdom, influenza seasons 2010/11 to 2016/17.英国 2010/11 至 2016/17 流感季节中 65 岁及以上人群接种和流感疫苗效果。
Euro Surveill. 2018 Sep;23(39). doi: 10.2807/1560-7917.ES.2018.23.39.1800092.
10
Pooled influenza vaccine effectiveness estimates for Australia, 2012-2014.2012 - 2014年澳大利亚流感疫苗综合有效性评估
Epidemiol Infect. 2016 Aug;144(11):2317-28. doi: 10.1017/S0950268816000819. Epub 2016 Apr 29.

引用本文的文献

1
Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.2024/25年度流感疫苗中期有效性:八项欧洲研究,2024年9月至2025年1月
Euro Surveill. 2025 Feb;30(7). doi: 10.2807/1560-7917.ES.2025.30.7.2500102.
2
How do large-scale population studies inform vaccine evaluations in England?大规模人口研究如何为英国的疫苗评估提供信息?
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxaf006.

本文引用的文献

1
The End of B/Yamagata Influenza Transmission - Transitioning from Quadrivalent Vaccines.B/山形流感病毒传播的终结——从四价疫苗过渡
N Engl J Med. 2024 Apr 11;390(14):1256-1258. doi: 10.1056/NEJMp2314801. Epub 2024 Feb 28.
2
Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023.2022/23 年度流感疫苗有效性中期报告:2022 年 10 月至 2023 年 1 月期间的六项欧洲研究。
Euro Surveill. 2023 May;28(21). doi: 10.2807/1560-7917.ES.2023.28.21.2300116.
3
Interim Estimates of 2022-23 Seasonal Influenza Vaccine Effectiveness - Wisconsin, October 2022-February 2023.
2022-23 季流感疫苗有效性的临时估计 - 威斯康星州,2022 年 10 月至 2023 年 2 月。
MMWR Morb Mortal Wkly Rep. 2023 Feb 24;72(8):201-205. doi: 10.15585/mmwr.mm7208a1.
4
Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23.2022/23 年加拿大,包括基因重配在内的独特遗传多样性的早期季节性甲型流感(H3N2)疫情的疫苗有效性估计。
Euro Surveill. 2023 Feb;28(5). doi: 10.2807/1560-7917.ES.2023.28.5.2300043.
5
Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021-2022 I-MOVE primary care multicentre study.欧洲甲型流感亚型流感疫苗有效性:2021-2022 年 I-MOVE 初级保健多中心研究结果。
Influenza Other Respir Viruses. 2023 Jan;17(1):e13069. doi: 10.1111/irv.13069. Epub 2022 Nov 21.
6
Representativeness, Vaccination Uptake, and COVID-19 Clinical Outcomes 2020-2021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: Cohort Profile Summary.英国牛津-皇家全科医师学院研究和监测网络 2020-2021 年的代表性、疫苗接种率和 COVID-19 临床结局:队列简介摘要。
JMIR Public Health Surveill. 2022 Dec 19;8(12):e39141. doi: 10.2196/39141.
7
Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis.重复接种流感疫苗会降低其效果吗?系统评价和荟萃分析。
Lancet Respir Med. 2023 Jan;11(1):27-44. doi: 10.1016/S2213-2600(22)00266-1. Epub 2022 Sep 21.
8
Effects of Confounding Bias in Coronavirus Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors.由于流感和 COVID-19 疫苗接种行为的相关性,导致 2019 年冠状病毒病(COVID-19)和流感疫苗效力测试阴性设计中的混杂偏倚的影响。
Clin Infect Dis. 2022 Aug 24;75(1):e564-e571. doi: 10.1093/cid/ciac234.
9
The impact of social and physical distancing measures on COVID-19 activity in England: findings from a multi-tiered surveillance system.社会和物理距离措施对英格兰 COVID-19 活动的影响:来自多层次监测系统的发现。
Euro Surveill. 2021 Mar;26(11). doi: 10.2807/1560-7917.ES.2021.26.11.2001062.
10
Protection provided by influenza vaccine against influenza-related hospitalisation in ≥65 year olds: Early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018/19.2018/19 年在英格兰推出新型佐剂疫苗的早期经验:流感疫苗对≥65 岁人群因流感相关住院的保护作用。
Vaccine. 2020 Jan 10;38(2):173-179. doi: 10.1016/j.vaccine.2019.10.032. Epub 2019 Oct 22.